SAM-e for the Treatment of Depression in Patients With Parkinson's Disease - Related Studies

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

This study is currently recruiting participants.

Study NCT00070941. Last updated on August 26, 2008. Information provided by National Center for Complementary and Alternative Medicine (NCCAM)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Parkinson's Disease
		Depression

2	Additional conditions recognized in this trial
		Depressive Disorder
		Parkinson Disease

3	More general conditions related to this trial
		Basal Ganglia Diseases
		Behavioral Symptoms
		Brain Diseases
		Central Nervous System Diseases
		Mental Disorders
		Mood Disorders
		Movement Disorders
		Nervous System Diseases
		Neurodegenerative Diseases
		Parkinsonian Disorders

4	Interventions listed in this trial
		SAM-e
		oral citalopram
		placebo

5	Additional drug interventions recognized in this trial
		Citalopram
		Dexetimide

6	More general drug interventions related to this trial
		Anti-Dyskinesia Agents
		Antidepressive Agents
		Antidepressive Agents, Second-Generation
		Antiparkinson Agents
		Autonomic Agents
		Central Nervous System Agents
		Cholinergic Agents
		Cholinergic Antagonists
		Molecular Mechanisms of Pharmacological Action
		Muscarinic Antagonists
		Neurotransmitter Agents
		Neurotransmitter Uptake Inhibitors
		Parasympatholytics
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Psychotropic Drugs
		Serotonin Agents
		Serotonin Uptake Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		National Center for Complementary and Alternative Medicine (NCCAM)
		Office of Dietary Supplements (ODS)